# A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers

> **NCT01186497** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 35 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rabeprazole sodium: Treatment E
- **DRUG:** Rabeprazole sodium: Treatment C
- **DRUG:** Rabeprazole sodium: Treatment D
- **DRUG:** Rabeprazole sodium: Treatment A
- **DRUG:** Rabeprazole sodium: Treatment B

## Key facts

- **NCT ID:** NCT01186497
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01186497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01186497, "A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01186497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*